2025 MSKCC Oncologic Toxicity Management Symposium: Novel Oncology Agents and Adverse Events — On Demand

Saturday, October 11, 2025, 8:00 AM – Thursday, April 30, 2026, 6:00 PM

As oncology rapidly advances, next-generation therapies continue to transform the cancer treatment landscape. Recorded live on June 20, 2025, this on-demand program offers a comprehensive, evidence-based overview of emerging treatments, their clinical impact, and the practical considerations surrounding their use in practice.

Faculty experts highlight the latest breakthroughs in cancer therapeutics and toxicity management—examining mechanisms of action, clinical applications, efficacy data, and strategies to mitigate treatment-related adverse events to ultimately enhance patient care and outcomes.

This activity is designed for oncologists, hematologists, researchers, nurse practitioners, physician assistants, pharmacists, and all healthcare professionals involved in cancer care.

Through this on-demand activity, you will develop a comprehensive understanding of the mechanisms, benefits, and risks associated with cutting-edge therapies, including:

• Radioligand Therapy – A novel approach that delivers targeted radiation to cancer cells, offering precise treatment with minimal damage to surrounding tissues. The session will focus on clinical applications, effectiveness, and strategies to manage radiation-related toxicity.
• Antibody Drug Conjugates (ADCs) – A breakthrough class of targeted cancer therapies designed to deliver highly potent chemotherapy directly to cancer cells. Experts will discuss the latest ADC developments, clinical benefits, and effective management of associated toxicities.
• CAR-T Cell Therapy – A groundbreaking immunotherapy that harnesses the body’s own immune system to fight cancer. This session will address treatment protocols and management of adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
• Bispecific Antibodies – A cutting-edge approach that redirects T-cells to attack tumor cells. Attendees will gain an understanding of the potential of Bispecific Antibodies, their clinical applications, and how to mitigate immune-related toxicities.
• Small Molecule Inhibitors (SMIs) – Targeted agents that block key pathways involved in cancer growth. This session will explore the role of SMIs in oncology, their therapeutic potential, and management of associated risks such as cardiovascular toxicity and metabolic disturbances.
• Immune Checkpoint Inhibitors (ICIs) – A revolutionary class of immunotherapies that enhance the body’s natural ability to fight cancer. Experts will discuss how ICIs are reshaping oncology, the challenges of immune-related adverse events (irAEs), and best practices for toxicity management.

For a complete list of speakers and presentations, please view the brochure from the live symposium.

1. Describe the mechanism of action, indications, and clinical efficacy of Radioligand Therapy, Antibody Drug Conjugates (ADCs), Bispecific Antibodies, CAR-T Cell Therapy, Small Molecule Inhibitors (SMIs), and Immune Checkpoint Inhibitors (ICIs).
2. Develop evidence-based strategies to identify, prevent, and manage treatment-related toxicities, such as cytokine release syndrome (CRS), neurotoxicity, immune-related adverse events (irAEs), and organ-specific toxicities.
3. Recognize the early signs of adverse reactions and implement effective interventions to reduce complications and improve patient safety.
4. Apply clinical case studies and expert insights to make informed, patient-centered decisions in oncology treatment planning.
5. Discuss how to balance treatment efficacy with toxicity management to optimize long-term patient outcomes.